C.M. Bidwell & Associates’s Integra LifeSciences IART Stock Holding History

C.M. Bidwell & Associates’s Portfolio IART Stock Details IART Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-2,305	Closed	-$132K	–	553
2023 Q1	$132K	Sell	2,305 -300	-12%	-$16.9K	0.1%	181
2022 Q4	$146K	Buy	+2,605	New	+$133K	0.12%	164
2022 Q3	–	Sell	-40	Closed	-$2K	–	506
2022 Q2	$2K	Buy	+40	New	+$2.4K	﹤0.01%	434
2021 Q3	–	Sell	-2,515	Closed	-$172K	–	585
2021 Q2	$172K	Buy	+2,515	New	+$178K	0.11%	175
2015 Q3	–	Sell	-7,119	Closed	-$196K	–	256
2015 Q2	$196K	Buy	+7,119	New	+$190K	0.04%	169

Other funds holding IART

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

C.M. Bidwell & Associates's IART Position: Q2 2023 in Review

C.M. Bidwell & Associates sold out of Integra LifeSciences (IART) in Q2 2023, closing a stake of 2,305 shares — an estimated $132K sold.

C.M. Bidwell & Associates first reported a position in IART in Q2 2015 and held it in 5 quarters. The position peaked at $196K in Q2 2015. 283 funds tracked by Wall St. Rank hold IART as of Q2 2023.

C.M. Bidwell & Associates reported no remaining Integra LifeSciences position as of Q2 2023 after selling out during the quarter.
C.M. Bidwell & Associates sold 2,305 Integra LifeSciences shares in Q2 2023, an estimated $132K.
C.M. Bidwell & Associates first reported a position in Integra LifeSciences in Q2 2015 and held it in 5 quarters.
C.M. Bidwell & Associates's Integra LifeSciences position peaked at $196K in Q2 2015.
283 funds tracked by Wall St. Rank held Integra LifeSciences as of Q2 2023.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2023, filed 14 Aug 2023.